| Name | No. | For Patients with | Purpose |
|---|---|---|---|
| MK2140-011 | 25-26 | A form of blood cancer called DLBCL, specifically the GCB subtype, which tends to respond better to treatment. |
This clinical trial is testing two different drug combinations to treat a type of blood cancer called DLBCL, specifically the GCB subtype. It compares a newer medicine called zilovertamab vedotin with an existing one called polatuzumab vedotin. Both are given alongside standard chemotherapy drugs. The goal is to see which combination works better at shrinking the cancer, keeping it from coming back, and causing fewer side effects. People in the trial have not yet received treatment for their DLBCL. By studying these options, researchers hope to improve outcomes and offer better choices for patients with this form of lymphoma. |
DSSG Group: Lymphoma & blood cancers
CLL18 / MOIRAI
| Name | No. | For Patients with | Purpose |
|---|---|---|---|
| CLL18 / MOIRAI | 24-34 | previously untreated chronic lymphocytic leukaemia (CLL) or small lymphocytic lymphoma (SLL) |
The CLL18 (MOIRAI) trial is testing different combinations of cancer drugs to treat chronic lymphocytic leukemia (CLL) in people who haven’t had treatment before. It compares fixed-duration treatments with a personalized approach that stops treatment early if the cancer becomes undetectable. The goal is to find the most effective and safest way to treat CLL while minimizing side effects and improving quality of life. |
ALIDHE
| Name | No. | For Patients with | Purpose |
|---|---|---|---|
| ALIDHE | 24-27 | IDH1m acute myeloid leukemia (AML) ineligible for intensive induction chemotherapy. |
The purpose of this study is to learn more about the safety and efficacy of the medication |
GIV-IN PV Trial
| Name | No. | For Patients with | Purpose |
|---|---|---|---|
| GIV-IN PV Trial | 24-99 | JAK2V617F-positive high-risk Polycythemia Vera patients |
The goal of this clinical trial is to compare the efficacy and safety of givinostat to hydroxyurea in Jak2V617F-positive high-risk polycythemia vera patients. |
CA057-001 (SUCCESSOR-1)
| Name | No. | For Patients with | Purpose |
|---|---|---|---|
| CA057-001 (SUCCESSOR-1) | 23-20 | Relapsed or refractory multiple myeloma |
The purpose of this study is to compare the efficacy and safety of mezigdomide (CC-92480), bortezomib and dexamethasone (MeziVd) versus pomalidomide, bortezomib and dexamethasone (PVd) in participants with relapsed or refractory multiple myeloma (RRMM) who received between 1 to 3 prior lines of therapy and who have had prior lenalidomide exposure. |
MOSAICC
| Name | No. | For Patients with | Purpose |
|---|---|---|---|
| MOSAICC | 19-41 | Myeloproliferative neoplasms and non-blood relative/friend controls. |
The MOSAICC study (MyelOproliferative neoplasmS: An In-depth Case-Control) is a UK-wide case-control study that aims to identify what causes MPNs and assess the quality of life and unmet needs of those who suffer from these conditions. |
Beigene 311-308 / MAHOGANY
| Name | No. | For Patients with | Purpose |
|---|---|---|---|
| Beigene 311-308 / MAHOGANY | 24-30 | Relapsed/Refractory Follicular or Marginal Zone Lymphoma |
The purpose of the study is to compare the efficacy of zanubrutinib plus obinutuzumab versus lenalidomide plus rituximab (R^2) in participants with relapsed/refractory (R/R) follicular lymphoma (FL), as measured by progression-free survival as determined by an independent review committee in accordance with the 2014 modification of the International Working Group on non-Hodgkin lymphoma (NHL) Criteria based on n positron emission tomography and computed tomography (PET/CT), and to compare the efficacy of zanubrutinib plus rituximab versus R^2 in participants with R/R marginal zone lymphoma (MZL), as measured by progression free survival (PFS) assessed by IRC in accordance with CT-based Lugano 2014 Criteria. |
BD – Bone Marrow/Blood
| Name | No. | For Patients with | Purpose | |
|---|---|---|---|---|
| BD – Bone Marrow/Blood | Healthy Volunteers for Research and Development Purpose |
|